Targeting cardiac hypertrophy through a nuclear co‐repressor

Heart failure entails the inability of the heart to pump blood to vital organs. One of the main risk factors for heart failure is the development of pathological hypertrophy. In this issue of EMBO Molecular Medicine, Li and coworkers show that NCoR1, a co‐repressor of transcription factors, inhibits...

Descripción completa

Detalles Bibliográficos
Autores principales: Grund, Andrea, Heineke, Joerg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835198/
https://www.ncbi.nlm.nih.gov/pubmed/31622030
http://dx.doi.org/10.15252/emmm.201911297
_version_ 1783466610798886912
author Grund, Andrea
Heineke, Joerg
author_facet Grund, Andrea
Heineke, Joerg
author_sort Grund, Andrea
collection PubMed
description Heart failure entails the inability of the heart to pump blood to vital organs. One of the main risk factors for heart failure is the development of pathological hypertrophy. In this issue of EMBO Molecular Medicine, Li and coworkers show that NCoR1, a co‐repressor of transcription factors, inhibits the transcriptional activity of MEF2 by stabilizing its complex with class II HDACs. By this mechanism, NCoR1 was identified as potent inhibitor of pathological cardiac hypertrophy and dysfunction.
format Online
Article
Text
id pubmed-6835198
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68351982019-11-08 Targeting cardiac hypertrophy through a nuclear co‐repressor Grund, Andrea Heineke, Joerg EMBO Mol Med News & Views Heart failure entails the inability of the heart to pump blood to vital organs. One of the main risk factors for heart failure is the development of pathological hypertrophy. In this issue of EMBO Molecular Medicine, Li and coworkers show that NCoR1, a co‐repressor of transcription factors, inhibits the transcriptional activity of MEF2 by stabilizing its complex with class II HDACs. By this mechanism, NCoR1 was identified as potent inhibitor of pathological cardiac hypertrophy and dysfunction. John Wiley and Sons Inc. 2019-10-17 2019-11-07 /pmc/articles/PMC6835198/ /pubmed/31622030 http://dx.doi.org/10.15252/emmm.201911297 Text en © 2019 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Grund, Andrea
Heineke, Joerg
Targeting cardiac hypertrophy through a nuclear co‐repressor
title Targeting cardiac hypertrophy through a nuclear co‐repressor
title_full Targeting cardiac hypertrophy through a nuclear co‐repressor
title_fullStr Targeting cardiac hypertrophy through a nuclear co‐repressor
title_full_unstemmed Targeting cardiac hypertrophy through a nuclear co‐repressor
title_short Targeting cardiac hypertrophy through a nuclear co‐repressor
title_sort targeting cardiac hypertrophy through a nuclear co‐repressor
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835198/
https://www.ncbi.nlm.nih.gov/pubmed/31622030
http://dx.doi.org/10.15252/emmm.201911297
work_keys_str_mv AT grundandrea targetingcardiachypertrophythroughanuclearcorepressor
AT heinekejoerg targetingcardiachypertrophythroughanuclearcorepressor

Ejemplares similares